Recent news includes an insider purchase of 100,000 shares by a company director, indicating insider confidence.

• A director of Accustem Sciences Inc. purchased 100,000 shares on January 3, 2025, signaling insider confidence in the company [N1].

Accustem has developed two clinically validated genomic tests addressing significant unmet needs in oncology diagnostics: MSC for lung nodules and StemPrintER for breast cancer recurrence risk. The tests have demonstrated strong prognostic performance in large patient cohorts and have been published in top-tier journals, supporting clinical credibility. The company’s strategy to commercialize through a laboratory partner and pursue reimbursement from CMS and private payers could enable market access. The large estimated US market opportunity exceeding $6 billion annually provides substantial revenue potential if commercialization milestones are achieved. Ancillary commodity testing offerings may enhance customer value and revenue diversification. Recent insider share purchases may indicate confidence in the company’s prospects.

Accustem is an early-stage clinical diagnostics company with limited financial resources and significant liquidity challenges, as reflected by a current ratio of 0.01 and ongoing net losses exceeding $1.7 million annually. The company has yet to achieve commercial scale and depends on successful transfer of testing to a commercial laboratory, obtaining CLIA certification, and securing reimbursement, all of which carry execution risks. The competitive landscape includes established diagnostic companies with broader product portfolios and market presence. Regulatory, reimbursement, and market acceptance risks may delay or limit revenue generation. The company’s small employee base and reliance on external partners may constrain operational capacity. Continued operating losses raise substantial doubt about the company’s ability to continue as a going concern without additional funding.

Accustem's moat is based on its proprietary genomic assays MSC and StemPrintER, which have been clinically validated in large prospective cohorts and published in leading scientific journals. The MSC test offers a novel microRNA-based approach to stratify lung nodules detected by low dose CT, potentially reducing overtreatment and healthcare costs. StemPrintER provides prognostic information on breast cancer recurrence risk based on tumor stemness biology, with validation against established assays like OncotypeDX. The company has exclusive licensing agreements for key intellectual property and plans to leverage a commercial laboratory partner for testing and reporting. However, the diagnostic oncology market is competitive with multiple established players offering alternative genomic and proteomic tests, which may limit Accustem's market penetration and pricing power. Regulatory and reimbursement hurdles also present barriers to entry for competitors but require successful navigation by Accustem to realize commercial benefits.

• Liquidity and Financial Sustainability: The company reported a current ratio of 0.01 as of December 31, 2025, indicating significant liquidity constraints. Ongoing net losses and accumulated deficits raise substantial doubt about the ability to continue as a going concern without additional capital.
• Regulatory and Reimbursement Risks: Commercialization depends on obtaining CLIA certification, CMS reimbursement, and private payer coverage. Delays or denials in these areas could limit market access and revenue.
• Competition: The diagnostic oncology market is competitive with established players offering alternative genomic and proteomic tests for lung and breast cancer, which may limit Accustem’s market penetration and pricing.
• Execution Risks: Successful transfer of testing to a commercial laboratory partner and scaling of operations are critical milestones. Failure to achieve these could delay commercialization.
• Dependence on Key Personnel and Partners: The company has a small team and relies on external laboratory partners. Challenges in attracting and retaining qualified personnel or partners could impair operations.

• Accustem Sciences Inc. is a clinical stage diagnostics company focused on developing and commercializing genomic tests for oncology care.
• The company’s main products are MSC (MicroRNA Signature Classifier) for lung nodules and StemPrintER, a 20-gene prognostic assay for early stage breast cancer.
• MSC is a 24-microRNA assay designed to help determine if lung nodules detected by low dose CT screening are benign or malignant, validated in over 5,000 patients and published in top-tier journals including Journal of Clinical Oncology.
• StemPrintER predicts risk of distant recurrence in luminal (ER+/HER2-negative) breast cancer patients, validated in over 3,000 patients including the TransATAC study, and has shown prognostic utility.
• The company estimates the US market opportunity for MSC at over $5.5 billion annually and for StemPrintER at over $800 million annually.
• Commercialization plans include transferring testing to a commercial laboratory partner (EmeritusDx), obtaining CLIA certification, and seeking reimbursement from CMS and other payers.
• The company plans to offer ancillary commodity testing (e.g., hereditary genetic testing, somatic mutation testing) to augment proprietary assays.
• Accustem is an emerging growth company under the JOBS Act and uses extended transition periods for accounting standards.
• Financial snapshot as of 2025-12-31 shows current assets of $49,446 and current liabilities of $4,951,071, resulting in a current ratio of 0.01, indicating liquidity challenges.
• Net loss for the year ended 2025 was $1,756,096 with basic and diluted EPS of -$0.12 per share.
• The company has accumulated deficits of approximately $9.78 million as of December 31, 2025.
• The company has four full-time employees as of December 31, 2025.
• An application for CMS coverage policy of the MSC test was filed with Novitas Solutions, Inc. in November 2025.
• Competition exists in lung cancer screening and breast cancer genomic testing from companies such as Biodesix, Veracyte, Hologic, Eurobio Scientific, Agendia, Exact Sciences, and others.
• Recent insider purchase of 100,000 shares by a director was reported on January 3, 2025.
• The company faces risks including ongoing operating losses, liquidity constraints, regulatory and reimbursement challenges, competition, and the need to manage growth and retain key personnel.